基本信息
浏览量:1097
职业迁徙
个人简介
More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and a first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma. Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD
研究兴趣
论文共 1607 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Haematologica (2024)
Darren Herweyer,Alexandros A. Kitos,Paul Richardson, Hussein Canoe,Jeffrey S. Ovens,Isabelle Laroche, Benoit Jolicoeur,Muralee Murugesu,Jaclyn L. Brusso
CRYSTAL GROWTH & DESIGNno. 4 (2023): 2576-2582
Paul G. Richardson, Brian G. Durie,Laura Rosinol,Maria-Victoria Mateos,Angela Dispenzieri,Philippe Moreau,Shaji Kumar,Noopur Raje,Nikhil Munshi,Jacob P. Laubach, Peter O'Gorman, Elizabeth O'Donnell,
HAEMATOLOGICAno. 11 (2023): 2894-2912
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn